Novo Nordisk's Pricing Pivot: A Monopoly's Slow Unraveling

Novo Nordisk faces margin pressure from Ozempic price cuts and clinical setbacks, despite strong Q2 results and ongoing buybacks.

The arithmetic of Novo Nordisk's decline is stark. From its late-January peak of 54.86 euros, the Danish pharma giant's shares have shed roughly 27 percent, closing Wednesday at 40.26 euros in Frankfurt trading. But the more telling number sits further out on the calendar: come January 2027, the company will cut the list price of Ozempic and Wegovy to 675 dollars a month — a concession that marks the end of an era as much as any clinical setback.

The pricing decision, framed by analysts as a direct response to political pressure from Washington and the encroaching competitive threat of Eli Lilly, crystallizes the dilemma Novo Nordisk now faces. For years, the company operated as the undisputed gatekeeper of the GLP-1 market, setting prices from a position of unassailable strength. That monopoly narrative is fracturing, and the market is no longer grading the company on its ability to manufacture Wegovy and Ozempic at scale, but on how long it can defend its margins while rivals circle.

A Guidance Lift That Fell Flat

The tension between operational strength and market skepticism was on full display this week. Novo Nordisk raised its full-year 2026 outlook after second-quarter results beat analyst expectations — adjusted operating profit climbed 11 percent to 33.4 billion Danish kroner, with revenue up 7 percent at constant exchange rates. Yet the stock fell 1.8 percent on Wednesday, a muted reaction that speaks volumes about where investor attention now sits.

CEO Mike Doustdar moved quickly to address the disconnect, telling investors the company would accelerate research and development and pursue targeted smaller acquisitions to bolster its pipeline. The message was unambiguous: better numbers alone would not be enough to restore confidence.

What's weighing on the stock is a string of clinical disappointments that have eroded the growth narrative. In early August, the late-stage ZEUS trial for Ziltivekimab failed to show a significant reduction in major cardiovascular events versus placebo, forcing the company to book a non-cash impairment charge in the third quarter. CagriSema, once the great hope for the next leg of growth, delivered weight loss of 23 percent against market expectations of roughly 25 percent — close, but in the unforgiving calculus of biotech investing, close is not enough.

The Buyback Machine Keeps Running

Amid the pipeline turbulence, the company's capital returns program has continued without interruption. Since February 4, 2026, Novo Nordisk has repurchased 27,884,179 B-shares at an average price of 279.01 Danish kroner apiece, totaling roughly 7.78 billion kroner. During the week of August 4-7 alone, the company bought back between 200,000 and 205,000 B-shares daily, while simultaneously transferring 3,144,604 shares under employee incentive programs.

The steady cadence of buybacks signals management's conviction in the company's long-term value, even as the share price languishes. In the first half of 2026, Novo Nordisk distributed 41.2 billion Danish kroner to shareholders.

Berenberg this week downgraded the stock to "Hold," arguing that the excitement around the oral version of Wegovy — once considered a central growth driver — is already priced into the current valuation. Other analysts counter that the stock now trades at a price-to-earnings ratio well below the sector average, making it attractive despite the headwinds.

A Company in Transition

There are bright spots. Novo Nordisk has launched Awiqli, the first once-weekly basal insulin, in the United States, and continues to expand production capacity aggressively. Its weight-loss franchise has also regained some ground against Eli Lilly in recent weeks, according to Reuters.

Still, the competitive picture is shifting. Analysts see Eli Lilly capturing a disproportionate share of the US Medicare market, and the 675-dollar list price for Ozempic and Wegovy — effective January 2027 — is a direct acknowledgment that the pricing power Novo Nordisk once wielded has limits.

With a market capitalization of 181 billion euros, Novo Nordisk remains one of Europe's largest pharmaceutical companies. But the question investors are now wrestling with is whether a discounted valuation can offset competitive pressure and clinical setbacks. The answer will become clearer once the market sees how the January 2027 price cut plays out — and whether Novo Nordisk can reclaim any of its former pricing authority in a market it created, but no longer controls.